Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
allogeneic hepatocyte-derived liver progenitor-like cells
- Development stage
- Unknown
- Lead developer
- Shanghai Celliver Biotechnology
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
Allogeneic hepatocyte-derived liver progenitor-like cells (HepLPCs) are an investigational cell therapy developed by RenJi Hospital, Shanghai Jiao Tong University School of Medicine, in collaboration with Shanghai Celliver Biotechnology. These cells are generated from human primary hepatocytes through a defined conversion protocol. HepLPCs are designed to treat liver cirrhosis by secreting high levels of matrix metalloproteinases (MMPs) and hepatocyte growth factor (HGF). They operate via paracrine mechanisms to induce apoptosis in hepatic stellate cells through STAT1-mediated pathways, effectively reducing liver fibrosis and promoting tissue repair. The therapy is currently being evaluated in Phase 1 clinical trials for safety and tolerability in patients with liver cirrhosis.
- Other names
- allogeneic hepatocyte-RenJi Hospital-liver cirrhosisallogeneic hepatocyteCongener Allogeneic Hepatocyte
Beyond the preview
Go deeper on allogeneic hepatocyte-derived liver progenitor-like cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on allogeneic hepatocyte-derived liver progenitor-like cells.